Combination treatment for low platelets from cancer therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have a solid tumor (like lung, breast, stomach, or colon cancer).
- Your platelet count is very low (under 50,000) and this is caused by your cancer treatments (like chemo, radiation, or targeted therapy).
- You are not pregnant, breastfeeding, and you agree to use birth control if needed.
- You have not had a blood clot or take medicines that raise your risk of clots (like certain heart medications).
- You have not used other platelet-raising drugs (like eltrombopag, romiplostim, or Nplate) in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This trial tests a new drug called Romiplostim N01 to see if it works better than the standard treatment (recombinant human thrombopoietin) for raising low platelets caused by cancer therapies, when other treatments have failed. It is for people aged 18-75 with solid tumors or blood cancers who have not responded to at least two platelet growth factors.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
Hear when a new Cancer Therapy-induced Thrombocytopenia (CTIT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.